Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and efficacy of cetuximab N01 in wild-type RAS colorectal cancer
ChiCTR2600128917Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: Distribution of adverse event types and Incidence rates of adverse events (AE) and serious adverse events (SAE). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600128917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128917.